SEARCH BLOG


2017 in Review: Part Two

With less than 24 hours to go to the new year, we're counting down to 2018 with a look back on all that happened this year
With less than 24 hours to go, we're counting down to 2018 with a look back on all that happened this year.  In our last entry, we mentioned catching up with the CRISPR-Cas9 … https://www.globalpatentsolutions.com/blog/2017/12/2017-review-part-two/

Allergan Patent Controversy Continues

Seeking protection from the patent challenges brought by generic drug makers, Allergan Plc made an unusual, and controversial, deal back in September.
Seeking protection from the patent challenges brought by generic drug makers, Allergan Plc made an unusual, and controversial, deal back in September that has continued to make wa… https://www.globalpatentsolutions.com/blog/2017/12/allergan-patent-controversy-continues/

WIPO & Pharma Team-Up with Pat-INFORMED Program

The Patent Information Initiative for Medicines (Pat-INFORMED) aims to create a common platform or database of key medicine patents & information, accessible to health professionals worldwide. 
Earlier this month, the World Intellectual Property Organization (WIPO), in partnership with the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), s… https://www.globalpatentsolutions.com/blog/2017/10/wipo-pharma-team-pat-informed-program/

Allergan Strikes Unconventional Deal to Protect Patents

Allergan, Plc has struck a deal with the Saint Regis Mohawk Tribe that will protect its patents.
Allergan, Plc has struck a deal with the Saint Regis Mohawk Tribe that will protect its patents on the popular eye medication, Restasis.  “The Tribe, a recognized sovereign tribal… https://www.globalpatentsolutions.com/blog/2017/09/allergan-strikes-unconventional-deal-protect-patents/

FluMist Flop: CDC Finds Inventive Vaccine Ineffective

The CDC has recently withdrawn its recommendation for the FluMist, leaving thousands of children and adults with only one option: the shot. 
Flu season is just around the corner, and the Centers for Disease Control and Prevention (CDC) and American Academy of Pediatrics have withdrawn their recommendations for the FluM… https://www.globalpatentsolutions.com/blog/2016/09/flumist-flop-cdc-findsinventive-vaccine-ineffective/

Mylan Pharmaceuticals Under Fire for EpiPen Price Jump

Mylan Pharmaceuticals is catching a lot of heat after raising the price of its EpiPen by over 400%.
Mylan Pharmaceuticals is catching a lot of heat after raising the price of its EpiPen by over 400% in the last few years.  Since acquiring the injectable allergy medicine in 2007,… https://www.globalpatentsolutions.com/blog/2016/08/mylan-pharmaceuticals-under-fire-epipen-price-jump/

Pharma Patents & The Battle of Brand V. Generic

The U.S. has seen a significant shift from brand-name prescription drugs to generics.
With a number of big brand-name drugs slated to lose patents this year, generic manufacturers are eager to push their products to market... And consumers are just as eager to get … https://www.globalpatentsolutions.com/blog/2016/08/pharma-patents-battle-brand-v-generic/

GSK Announces New "Graduated" Approach to Patents

GlaxoSmithKline recently made the shocking announcement that it will no longer seek patents for pharmaceuticals in developing and other low-income countries.
GlaxoSmithKline recently made the shocking announcement that it will no longer seek patents for pharmaceuticals in developing and other low-income countries.  In a recent press r… https://www.globalpatentsolutions.com/blog/2016/04/gsk-announces-new-graduated-approach-patents/

Pfizer Settles Seven Year Lawsuit with $784 Million

Just recently, Pfizer announced that its Wyeth unit will pay nearly $785 million to settle a long-standing lawsuit regarding its heartburn drug, Protonix.
  Just recently, Pfizer announced that its Wyeth unit will pay nearly $785 million to settle a long-standing lawsuit regarding its heartburn drug, Protonix.   Wyeth first came … https://www.globalpatentsolutions.com/blog/2016/03/pfizer-settles-seven-year-lawsuit-784-million/

WTO Extends Waiver on Patents for LDCs

The World Trade Organization recently decided to extend a waiver on patents for pharmaceutical products for Least-Developed Country members (LDC).
The WTO Council for Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreed to an extension of the pharmaceutical IP waiver for LDCs on Friday, allowing members to av… https://www.globalpatentsolutions.com/blog/2015/11/wto-extends-waiver-patents-ldcs/

New Cure for Hepatitis C: Patent Litigation & High Price

A new cure for hepatitis C is causing controversy with its $84,000 price and string of patent disputes.
A new cure for hepatitis C is causing controversy with its $84,000 price tag for 12 weeks of treatment.  Gilead Sciences Inc.’s new drug, Sovaldi, may cost roughly $1,000 per pill… https://www.globalpatentsolutions.com/blog/2014/07/new-cure-hepatitis-c-patent-litigation-high-price/

Antibiotic Resistance, Patents, and A Global Health Plan

With antibiotics now available to lower-income countries, the rate at which bacteria are evolving is rapidly increasing.
As global antibiotic use continues to rise, so does the number of drug-resistant bacteria.  Studies by the Center for Disease Dynamics, Economics & Policy (CDDEP) and Princeton Un… https://www.globalpatentsolutions.com/blog/2014/07/antibiotic-resistance-patents-and-global-health-plan/

Bowman v. Monsanto Co. -- A Watershed Moment for Biotech Patents?

This is a well-covered topic, but the implications for biotech patents are so significant that it is worthy of understanding by all intellectual property professionals. Whether you are a patent attorney, a patent agent, a person performing patent search,…
By Ralph "Donnie" Turlington, Research Analyst                         On March 19, 2013 the U.S. Supreme Court decided in favor of the chemical and agricultural biotechnology … https://www.globalpatentsolutions.com/blog/2014/06/bowman-v-monsanto-co-watershed-moment-biotech-patents/

THE FATE OF EMBRYONIC STEM CELL PATENTS

This is a pretty detailed blog post. It is focused very specifically at describing the fate of embryonic stem cell patents.
THE FATE OF EMBRYONIC STEM CELL PATENTS By Alexcia Linthicum | April 23, 2014   In 1998, Dr. James A. Thomson isolated human embryonic stem (ES) cells and he assigned a … https://www.globalpatentsolutions.com/blog/2014/06/fate-embryonic-stem-cell-patents/

South Africa Rejects Big Pharma's "Satanic" Campaign

The Innovative Pharmaceutical Association South Africa recently rejected a U.S. pharmaceutical campaign in opposition to th...
The Innovative Pharmaceutical Association South Africa recently rejected a U.S. pharmaceutical campaign in opposition to the proposed changes of South African intellectual prope… https://www.globalpatentsolutions.com/blog/south-africa-rejects-big-pharmas-satanic-campaign/

FTC Changes HSR Act for Pharmaceutical Companies

The Federal Trade Commission recently revised the rules to the HSR Act regarding when pharmaceutical companies are required t...
The Federal Trade Commission recently revised the rules to the HSR Act regarding when pharmaceutical companies are required to report a transfer of exclusive patent rights to the … https://www.globalpatentsolutions.com/blog/ftc-changes-hsr-act-pharmaceutical-companies/

Pharmaceutical Company's Global Initiative Cuts Jobs by 20%

Merck & Co., one of the world’s leading pharmaceutical companies, recently announced that it will cut 8,500 jobs in an ef...
Merck & Co., one of the world’s leading pharmaceutical companies, recently announced that it will cut 8,500 jobs in an effort to restructure the company and revive its struggling … https://www.globalpatentsolutions.com/blog/pharmaceutical-companys-global-initiative-cuts-jobs-20/

Three Interesting Patents to Keep an Eye on

Let’s take a quick break from the constant stream of patent troll news and circle back to where it all began – innovation.&nb...
Let’s take a quick break from the constant stream of patent troll news and circle back to where it all began – innovation. As important as it is to keep an eye on all the politic… https://www.globalpatentsolutions.com/blog/three-interesting-patents-keep-eye/

Eli Lilly Sues Canada for "Unfair" Patent Ruling

U.S. pharmaceutical giant Eli Lilly is at odds with the Canadian government over invalidated patents on its drugs Strattera, ...
U.S. pharmaceutical giant Eli Lilly is at odds with the Canadian government over invalidated patents on its drugs Strattera, used to treat ADHD, and Zyprexa, an antipsychotic medi… https://www.globalpatentsolutions.com/blog/eli-lilly-sues-canada-unfair-patent-ruling/

South Africa Proposes Intellectual Property Policy

South Africa is currently looking for ways to implement a proposed National Policy on Intellectual Properties in an effort to...
South Africa is currently looking for ways to implement a proposed National Policy on Intellectual Properties in an effort to restrict patent evergreening and increase innovation … https://www.globalpatentsolutions.com/blog/south-africa-proposes-intellectual-property-policy/

« Previous 12 Next »

Latest Posts

Posts By Category


RECEIVE A SYNOPSIS OF OUR STAFF BIOGRAPHIES




DOWNLOAD WHITEPAPERS